注册号: Registration number: |
ChiCTR2000029387 |
最近更新日期: Date of Last Refreshed on: |
2020-03-02 |
注册时间: Date of Registration: |
2020-01-29 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
利巴韦林联合干扰素-α,洛匹那韦/利托那韦联合干扰素-α及利巴韦林联合洛匹那韦/利托那韦联合干扰素-α对轻中度新型冠状病毒肺炎患者有效性和安全性的随机对照研究 |
Public title: |
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
利巴韦林联合干扰素-α,洛匹那韦/利托那韦联合干扰素-α及利巴韦林联合洛匹那韦/利托那韦联合干扰素-α对轻中度新型冠状病毒肺炎患者有效性和安全性的随机对照研究 |
Scientific title: |
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
曾妍茗 |
研究负责人: |
陈耀凯 |
Applicant: |
Yanming Zeng |
Study leader: |
Yaokai Chen |
申请注册联系人电话: Applicant telephone: |
+86 023-65481658 |
研究负责人电话: Study leader's telephone: |
+86 023-65481658 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
doczym@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yaokaichen@hotmail.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
重庆市沙坪坝区歌乐山镇109号重庆市公共卫生医疗救治中心 |
研究负责人通讯地址: |
重庆市沙坪坝区歌乐山镇109号重庆市公共卫生医疗救治中心 |
Applicant address: |
109 Baoyu Road, Shapingba District, Chongqing, China |
Study leader's address: |
109 Baoyu Road, Shapingba District, Chongqing, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
重庆市公共卫生医疗救治中心 |
||
Applicant's institution: |
Chongqing Public Health Medical Center |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
2020-002-01-KY |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
重庆市公共卫生医疗救治中心伦理委员会 |
||
Name of the ethic committee: |
The Institution Review Board of Chongqing Public Health Medical Center |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2020-01-28 | ||
伦理委员会联系人: |
陈亚玲 |
||
Contact Name of the ethic committee: |
Yaling Chen |
||
伦理委员会联系地址: |
重庆市沙坪坝区109号重庆市公共卫生医疗救治中心 |
||
Contact Address of the ethic committee: |
Chongqing Public Health Medical Center, 109 Baoyu Road, Shapingba District, Chongqing, China |
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 023-65518197 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
重庆市公共卫生医疗救治中心 |
||||||||||||||||||||||
Primary sponsor: |
Chongqing Public Health Medical Center |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
重庆市沙坪坝区歌乐山镇109号重庆市公共卫生医疗救治中心 |
||||||||||||||||||||||
Primary sponsor's address: |
109 Baoyu Road, Shapingba District, Chongqing, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
重庆市科学技术委员会 |
||||||||||||||||||||||
Source(s) of funding: |
Chongqing Science and Technology Bureau |
||||||||||||||||||||||
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
其它 | ||||||||||||||||||||||
Study phase: |
N/A |
||||||||||||||||||||||
研究目的: |
评价三种抗病毒方案治疗轻中度新型冠状病毒感染的肺炎患者的疗效和安全性。 |
||||||||||||||||||||||
Objectives of Study: |
Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate novel coronavirus pneumonia. |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
(1)年龄18~65岁; (2)确诊为普通型新型冠状病毒感染的肺炎患者; (3)自愿签署受试者知情同意书,并愿意接受随访; (4)研究者认为,受试者总体状况不影响试验的评估和完成。 |
||||||||||||||||||||||
Inclusion criteria |
(1) 18–65 years of age; (2) Diagnosed as mild to moderate COVID-19; (3) Be willing to sign informed consent; (4) The clinical assessment and condition of the subject does not influence the completion of the study. |
||||||||||||||||||||||
排除标准: |
(1)排除重度、危重度新型冠状病毒感染的肺炎; (2)妊娠期和哺乳期妇女; (3)入选时检测到以下结果:ALT和AST>正常值的5倍,肌酐清除率<50 ml/min; (4)对LPV/r和利巴韦林、干扰素过敏者; (5)HIV感染者; (6)血红蛋白病患者; (7)有严重心、脑、肺、肾、肿瘤等基础疾病; (8)未获得知情同意者; |
||||||||||||||||||||||
Exclusion criteria: |
(1) Patients are diagnosed as a case of severe NCIP; (2) Patients are pregnant or breastfeeding women; (3) Patients have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5×UNL or creatinine clearance <50 ml / min; (4) Patients are allergic or intolerant to the proposed antiviral therapeutic drugs; (5) Patients are HIV-positive; (6) Patients with hemoglobin disease (7) Patients have severe heart disease, brain disease, lung disease, kidney disease, tumor or other severe systemic diseases; (8) Patients are not willing to provide signed informed consent. |
研究实施时间: Study execute time: |
从From2020-01-25至To 2021-01-25 |
征募观察对象时间: Recruiting time: |
从From2020-01-25至To 2020-03-31 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|